Update on the DSM-5

Katharine Phillips, MD

Director of Research for Adult Psychiatry and
Senior Research Scientist
Rhode Island Hospital

Professor, Psychiatry and Human Behavior
Alpert Medical School of Brown University
Providence, Rhode Island

Member, DSM-5 Task Force

Dr. Phillips describes the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) and discusses the kinds of proposed changes and how they'll be implemented in the publication.

Helping Children and Teens With Anxiety Disorders and Depression

Understanding New Research and Treatment

When anxiety takes over, it interferes with your child’s ability to cope with fear, worry, and depression — and treatment is necessary.

Early intervention is critical. Waiting for your child to mature or grow out of these behaviors may not be the right approach. In some cases children may develop chronic anxiety and depression, which is often associated with substance abuse and other high-risk behaviors.

Anxiety and Cardiovascular Health

Carl "Chip" J. Lavie, MD
Professor of Medicine
Medical Director, Cardiac Rehabilitation and Prevention
Director, Stress Testing Laboratory
John Ochsner Heart and Vascular Institute
Ochsner Clinical School – The University of Queensland School of Medicine
New Orleans, Louisiana

Dr. Lavie, who practices cardiology and internal medicine, discusses the link between anxiety and other psychological stress for patients with cardiovascular disease.

Teens Outrunning Anxiety

Solome Tibebu, personal storyI’m 21 years old, and besides my busy schedule as a full-time student the University of St. Thomas in St. Paul, Minnesota, keeping a regular running and yoga schedule, work, and trying to balance a social life, I am also the founder and Executive Director of Anxiety In Teens Non-Profit, LLC.

Attention Bias Modification of CBT Treatment of Panic Disorder

Eligibility Criteria

Men and women at least 18 years old with a primary diagnosis of panic disorder, as evaluated by the SCID for DSM-IV criteria.

Exclusion Criteria

Participants cannot have agoraphobia that limits their ability to travel to weekly sessions. A lifetime history of bipolar disorder, schizophrenia, or psychosis also prohibits participation. Participants cannot be at current risk of suicide, or have had an eating disorder or substance or alcohol abuse or dependence within the last six months. Serious or unstable medical illness also prohibits participation.

Psychotropic medication is permitted if the participant has been on medication for at least six weeks, and has been on a stable dose of medication for at least four weeks.

Within the last three months, participants cannot have received psychotherapy directed at the treatment of panic disorder.

Prior non-response to adequately delivered exposure therapy also disqualifies.


The purpose of this study is to examine the efficacy of augmenting CBT with cognitive bias modification — a new and promising means of reducing cognitive biases thought to underlie the development and maintenance of anxiety disorders — in the treatment of panic disorder. All participants will receive seven sessions of CBT. During their CBT visits, half of the participants will receive cognitive bias modification; the other half will complete a placebo task.